Design and Optimization of Tumor Treating Fields Device for Targeted Therapy in Cancer

Introduction: Tumor Treating Fields (TTFields), which use low-intensity, intermediate-frequency electric fields, provide promising non-invasive treatment. However, TTF systems still face challenges in optimization and practical implementation. Aim: This study is aimed to design and optimizing TTF devices. Materials and Methods: The TTField-generating device was built around a Class A amplifier circuit. The final experimental setup generated an alternating electric field in the frequency range of 100–300 kHz, with a field intensity of 3 V/cm. Ehrlich ascites carcinoma (EAC) cell line was used to establish solidtumor in each mouse abdomen (5 x 106 cells). After eight days, group A (n=3) was exposed to TTFields for 7 days. A caliper was used to record the changes that occur in the tumor diameters twice a week. Fresh blood samples were collected from mice in the two groups to make CBC, Liver and Kidney Functions. EAC was harvested from each mouse for making apoptosis using a flow cytometer. Results: The findings show a sustained increase in tumor diameters and reduced morbidity in the control group. On the other hand, there was a significant initial reduction followed by stabilization and normal morbidity in group A. For CBC analysis, treated mice showed reduced hemoglobin. In liver and kidney functions, there were elevated bilirubin and urea in treated mice. Apoptosis increased progressively in GA compared to the control group. Conclusion: The study concludes the effectiveness of the "TTFs" from the designed device in reducing tumor size without fatal effects on other organs.